Member Info for mysteryguy

@ scott - dude please just shut up with the endless ranting on GL. I think i speak for many people here that it's tiresome. We are all down on our investment and off course we are all looking to recoup as much as we can to come close to a break even but your endless repetitive comments serve no purpose. switch it up.

also are you actually still invested here?

let's see, a rise to 77 by lunch before declining 2-3% when NASDAQ opens. finishing at 74-76. Resulting in no difference for the day. at least that will be different to the normal 3% up 3% down constantly.

Usual PM drop. The pro's must be buying at the PM dip and selling at the AM rise

@eviking - are you now saying this as you've sold your stake and want to feel better? Below 1p? Utter nonsense. I am often not the most positive about this company and for reasons that have been proved correct and I do get the endless damper thrown at me but even I am not that unrealistic about this company.

Sadly I feel it is extremely unlikely Motif will get FDA approval for the ABSSI route, anybody who did there research would have known a further trial was inevitable but given the lack of transparency and things still in the air it seems almost certain to be a dead end. My only hope is Motif can get further funding and pursue its in vivo preclinical studies for toxoplasma and cystic fibrosis but then sadly we are back to pre-clinical trials but we would then have a better chance to all recover atleast most of our losses.

@daytrader - I already have and now I am asking what others think. This is a forum discussion page right?

I am reliability inexperienced when it comes to the pharma industry, however I correctly predicted that option 3 would be the outcome from the FDA minutes meeting. I was called a de-ramper, negative and a pessimist but I was thinking with my head not my heart. I also don't see the trial being a small one and I think there is a strong chance that Motif may not continue down the ABSSI route it is proving to be problematic. My question to the more experienced personal is if Motif can gain further funding (after September when cash runs out) can they keep afloat through the other ventures they have entered in the Toxoplasma and Cystic Fibrosis studies and if so do you think a 12month period is realistic for the share price to get to the 20p mark should the market react well to these reliability cheap studies? Motif have clearly entered into these two studies to not only diversify but also as a back up for the potential closure of the ABSSI route. What are people's thought?
I would also like to say at this stage I don't advocate anyone selling just yet. It's a defo Hold for now.

Said it countles times a further trial will be required. Personally I feel there is a strong chance they may not continue down the ABSSI route it's proving to me problematic and funding is Motif's big challenge now. They may decide to focus more on there two relatively inexpensive ventures the toxiplasma and cysystic fybrosys ventures. Best we can hope for is the market reacts well to these ventures and in the next 12 months we can get close to the 20p region so most of us can atleast break even. Fingers crossed for the dial in on Thursday we may be pleasantly surprised with just a very small trial required though I feel it's unlikely. Hang on to the share for now.
Good luck all.

@Sankeys you aren't starting fights again are you kid? Behave

They are probably scaling the size of the trial they will need to conduct to provide an informative announcement to the market. Nonetheless the delay isn't good.

Yes ofcourse it is. It provides a path forward for Motif Bio and its investors

Wasn't Motif's whole point of requesting a meeting with the FDA to create a clear dialogue with them with what they must do in order to get approval. So all the announcement will state is what Motif need to do next regarding the additional data required for liver toxicity issues.

Come on where's all the people who love PMO at?

@eviking - Yea next week.

https://www.proactiveinvestors.co.uk/companies/stocktube/13472/motif-bio-s-graham-lumsden-updates-on-fda-discussions-and-iclaprim-potential-13472.html

''Feedback from that meeting is expected in early June.''

All the articles are starting to emerge now on how premier oil is a must buy. Further proof this is rigged

Jimmybob - fool! how am i trying to scare people? I am also invested here.

@ GoBIGorGoHome
Motif's acknowledged additional data will likely be required to address the agency’s concern about a risk of liver toxicity, although it will wait to hear what the FDA has to say before deciding the size and scope of any potential study.

Data and study are the two words jumping out to me.

@Jimmybob ha! hilarious....My opinion is what I deem to be the realistic outcome following the release of the minute meeting with the FDA. Of-course I sincerely hope it's either option 1 or 2 but with the below statement on proactive to me it's obvious option 3 further trial will be required. You don't really get additional data by simply doing a label change and certainly not concrete enough to deem the drug safe. Also while placing the drug on a post approval commitment would provide data perhaps required it also does't seem like a viable option as it's not enough in the short term to facilitate with the FDA it also seems like something that could have been approved earlier if so.

Motif Bio PLC's (LON:MTFB) Graham Lumsden chats to Proactive London's Andrew Scott after a meeting earlier this month with Food and Drug Administration officials to chart the next steps to get US regulators to approve their antibiotic iclaprim.

Motif's acknowledged additional data will likely be required to address the agency’s concern about a risk of liver toxicity, although it will wait to hear what the FDA has to say before deciding the size and scope of any potential study.

but with Motif teaming up in several avenues to show the benefits of Iclaprim (Not just the ABBSI route) I do see a good chance the share price will get back to the 20-30p region within 12 months so must of us can at least break even. Nothing ventured nothing gained. But it is a long road ahead for now.

I feel like i am hitting myself against a brick wall here. It is obviously going to be option 3 a further trial required which isn't going to send the shares sky rocketing in the short term.

people are talking as if its just moments away from soaring up. Motif still have action to do. Don't get carried away people come on.

My personal deadline for BPC is end of the year.